On one side, as the consumption of tafamidis meglumine is associated with transthyretin amyloidosis condition, we identified all patients with at least one tafamidis meglumine delivery and at least one of the selected cardiac conditions (heart failure, arrhythmias, conduction disorders, cardiomyopathies) or at least one tafamidis meglumine delivery prescribed by a cardiologist as ATTR-CM patients. This evidence concerns the gene TTR and conduct disorder.